[
  {
    "ts": null,
    "headline": "Gilead announces PURPOSE 2 trial data published in NEJM",
    "summary": "Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. The study found that twice-yearly lenacapavir for pre-exposure prophylaxis, or PrEP, was highly efficacious at reducing HIV infections, reducing them by 96% compared to background",
    "url": "https://finnhub.io/api/news?id=ab7d3b33a5950d1c93fa8a6bfa599eb05723722ea422a3808b50bfdfd2c56994",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732831527,
      "headline": "Gilead announces PURPOSE 2 trial data published in NEJM",
      "id": 131697494,
      "image": "",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 trial evaluating twice-yearly lenacapavir for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. The study found that twice-yearly lenacapavir for pre-exposure prophylaxis, or PrEP, was highly efficacious at reducing HIV infections, reducing them by 96% compared to background",
      "url": "https://finnhub.io/api/news?id=ab7d3b33a5950d1c93fa8a6bfa599eb05723722ea422a3808b50bfdfd2c56994"
    }
  },
  {
    "ts": null,
    "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know",
    "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=be79ff9b12a870ba52cc3bed6c3ad555ceac35ff9233158f6868cb1ac637c6eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732802412,
      "headline": "Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know",
      "id": 131688995,
      "image": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=be79ff9b12a870ba52cc3bed6c3ad555ceac35ff9233158f6868cb1ac637c6eb"
    }
  },
  {
    "ts": null,
    "headline": "Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial",
    "summary": "The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) against once-daily oral Truvada.",
    "url": "https://finnhub.io/api/news?id=73b95cf4e270d7aa20fae986546e845a27648f5107868c6c47a43d01c16c494a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732795644,
      "headline": "Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial",
      "id": 131683108,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/11/CTA-2-Gileadd-Shutterstock_2113618628.jpg",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) against once-daily oral Truvada.",
      "url": "https://finnhub.io/api/news?id=73b95cf4e270d7aa20fae986546e845a27648f5107868c6c47a43d01c16c494a"
    }
  }
]